In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 692 ( 2023-04-19)
Abstract:
A major goal for influenza vaccines is to elicit broadly reactive immune responses that can protect against many strains of the virus. Widge et al . and Andrews et al . report results of a phase 1 clinical trial testing a vaccine that may get closer to this goal. Widge et al . demonstrated that immunization with one or two doses of an H1 hemagglutinin stabilized stem nanoparticle (H1ssF) vaccine was safe in recipients and elicited durable neutralizing antibody responses. Andrews et al . found that memory B cell responses elicited by H1ssF vaccination were broadly cross-reactive and targeted two conserved epitopes on the H1 stem. Together, these studies highlight the potential of H1ssF and similar stem-only immunogens as influenza vaccines. —CM
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.ade4976
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
Bookmarklink